NPSP January 9, 2014 In August, I reported: First suggested here at $6.65 and then again at $5.50 or so, NPSP closed Friday at $22.59, for about a quadruple. I celebrated by taking some profits; yet Guru writes of the company’s wildly expensive drug ($295,000 a year): “There are probably 1,000 to 3,000 people in the US who could really benefit from Gattex. Could be more. That’s $300 million to $900 million in the US. They will launch in Europe where the market is similarly sized. For sure this is a $500 million in peak sales. Every year. For a long time. No competition. No one even trying to compete. This product could extend survival. Meanwhile, they have another product, for hypoparathyroidism — to supply the missing parathyroid hormone. Will file this year. Launch end of next year. Another $300 million potential market in the US. Then they get a royalty from Amgen of $100 million. The stock should hit 36 over the next year.” So I’ve kept some. Yesterday, it closed at $35.11, which is close enough. I took my six-fold gain (thanks, Guru) and sold the rest. Have a great day. I feel a political screed coming on, but for now, you’re spared.